Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $86,735.43 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,817 shares of Akero Therapeutics stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $86,735.43. Following the sale, the chief financial officer now directly owns 38,335 shares of the company’s stock, valued at approximately $1,180,334.65. This trade represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Akero Therapeutics Stock Performance

Shares of AKRO stock opened at $28.89 on Friday. The stock’s 50-day moving average is $30.81 and its two-hundred day moving average is $27.13. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $37.00. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of -7.70 and a beta of -0.23.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Citigroup started coverage on Akero Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $65.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.83.

Hedge Funds Weigh In On Akero Therapeutics

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares during the period. Eastern Bank purchased a new stake in shares of Akero Therapeutics in the third quarter valued at about $100,000. Summit Financial Wealth Advisors LLC acquired a new stake in shares of Akero Therapeutics during the third quarter worth about $205,000. Victory Capital Management Inc. purchased a new position in shares of Akero Therapeutics during the third quarter worth about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Akero Therapeutics during the third quarter worth about $265,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.